15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 12 firms covering Viridian Therapeutics Inc, 12 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets range widely, $22.00 to $61.00 (about 2.8x), a sign of real disagreement on valuation. The average target of $37.00 sits 90% above the current $19.50. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.93 next quarter toward $-2.63 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS12 ratings
Strong Buy
Strong Buy00%
Buy12100%
Hold00%
Sell00%
Strong Sell00%
Based on 12 analysts giving stock ratings to Viridian Therapeutics Inc.
As of Jul, 12 of 12 firms rate VRDN a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
VRDN EPS & revenue forecast
EPS · NEXT QUARTER
$-0.93
Range $-1.33 – $-0.37 · 11 analysts · +173% YoY
Next period, 11 analysts expect Viridian Therapeutics Inc to earn $-0.93 a share (range $-1.33 – $-0.37), versus $-0.34 a year earlier. Full-year consensus is $-3.80, growing to $-2.63 the year after.
REVENUE · NEXT QUARTER
$9.4M
Range $0 – $79.0M · 11 analysts · -87% YoY
Revenue is expected to reach $9.4M (range $0 – $79.0M), -86.7% year-over-year. Full-year consensus is $27.7M, rising to $231.5M next year.
Top analysts covering Viridian Therapeutics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on VRDN.
#1
Serge Belanger
Needham · Rank #83
Buy
$34.00+74.4% to target
Overall win rate
48%
+ Follow
#2
Laura Chico
Wedbush · Rank #122
Buy
$43.00+120.5% to target
Overall win rate
40%
+ Follow
#3
Douglas Tsao
HC Wainwright & Co. · Rank #212
Buy
$22.00+12.8% to target
Overall win rate
35%
+ Follow
#4
Leland Gershell
Oppenheimer · Rank #254
Buy
$36.00+84.6% to target
Overall win rate
37%
+ Follow
#5
Derek Archila
Wells Fargo · Rank #350
Buy
$31.00+59.0% to target
Overall win rate
32%
+ Follow
VRDN stock forecast FAQ
What is VRDN's average 12-month price target?+
The 11 analysts with a live target average $37.00 for Viridian Therapeutics Inc over the next 12 months, ranging from a $61.00 high to a $22.00 low.
Is VRDN stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 12 analyst ratings, 12 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for VRDN?+
The Street-high target is $61.00 (BTIG), and the Street-low is $22.00 (HC Wainwright & Co.). The average of all 11 active targets is $37.00.
How many Wall Street analysts cover VRDN?+
12 analysts have an active rating on Viridian Therapeutics Inc, and 11 firms carry a live 12-month price target.
Who is the most accurate analyst covering VRDN?+
Among analysts who currently cover VRDN, Serge Belanger of Needham has the strongest overall Quantellect track record (Rank #83). Their current call is Buy with a $34.00 target.
What is Viridian Therapeutics Inc's projected EPS for next quarter?+
The consensus estimate is $-0.93 per share (range $-1.33 – $-0.37) across 11 analysts. Full-year EPS is projected at $-3.80, rising to $-2.63 the following year.
How much revenue is Viridian Therapeutics Inc expected to report next quarter?+
Consensus revenue is $9.4M (range $0 – $79.0M). Full-year revenue is projected at $27.7M, growing to $231.5M next year.
Have analysts been upgrading or downgrading VRDN lately?+
As of Jul, 12 of 12 firms rate VRDN a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their VRDN calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
